Lucrèce Ahovègbé is a pharmacist from Benin. She is enrolled in a PhD program with ACE-PHARMBIOTRAC-Uganda. This abstract is a product of a collaboration she established with Professor Thomson’s team at the MRC-University-of-Glasgow-Centre-for-Virus-Research. Lucrèce recently got a paper accepted for publication in the Journal of Hepatology with the CVR team.

Maryam’s training and research are based in the field of epidemiology, with a specific focus on clinical epidemiology. She has a BSc in Biology and an MSc in Clinical Epidemiology. Maryam has completed her PhD in Epidemiology at the UNSW, where she now is a Senior Lecturer.

Pinelopi Antonakaki, social worker, Msc addiction prevention and treatment, working with people who use drugs with hcv and liver diseases

Giuliano Rizzardini, MD, is Director of the Department of Infectious Diseases at Luigi Sacco, a teaching hospital in Milan, Italy, and Visiting Professor at the School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa. His research on antiretrovirals, antivirals, and antibiotics is documented in over 300 peer-reviewed articles.

I am a PhD student at the School of Population and Public Health at the University of British Columbia. My primary research interest is assessing the impact of direct-acting antivirals treatment on the risk of extrahepatic manifestations among people living with hepatitis C infection.

Mrs Fabienne Marcellin is a research engineer in the French Institute for Health and Medical Research (Inserm). She works on issues related to access to care and patient-reported outcomes for people with hepatitis C or HIV-HCV co-infection.

Max Spaderna is an Assistant Professor of Psychiatry in the Community Psychiatry division of the University of Maryland Medical School. His research interests involve improving access to mental health treatment, with a focus on patients with opioid use disorder.

Ι am 55 years old Hepatologist at the GENERAL HOSPITAL OF LAMIA-GREECE.I have been dealing with the treatment of patients with hepatitis C for 10 years.Εspecially treatment of people who receiving buprenorphine replacement therapy or using intravenous substances at Central Greece.I have participated in your conference several times with poster.